SAN DIEGO (AP) — SAN DIEGO (AP) — Cardiff Oncology, Inc. (CRDF) on Tuesday reported a loss of $13.9 million in its second quarter.
The San Diego-based company said it had a loss of 21 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The molecular diagnostic company posted revenue of $121,000 in the period, also falling short of Street forecasts. Three analysts surveyed by Zacks expected $150,000.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRDF at https://www.zacks.com/ap/CRDF
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)